Fenofibrate News and Research

RSS
Fenofibrate is a drug used to treat high levels of cholesterol and triglycerides in the blood. Fenofibrate is being studied in the treatment of advanced cancers in young patients and in the treatment of other conditions. It is a type of antilipidemic agent. Also called Lofibra and TriCor.
Could fenofibrate be an effective antiviral against SARS-CoV-2?

Could fenofibrate be an effective antiviral against SARS-CoV-2?

Early clinical data demonstrates the efficacy of existing drug in treating COVID-19

Early clinical data demonstrates the efficacy of existing drug in treating COVID-19

Intensive interventions in type 2 diabetes reduce risk of cardiovascular autonomic neuropathy

Intensive interventions in type 2 diabetes reduce risk of cardiovascular autonomic neuropathy

NTU-incubated start-up plans clinical trial of new slow-release pill for Parkinson’s disease

NTU-incubated start-up plans clinical trial of new slow-release pill for Parkinson’s disease

Cholesterol-lowering drugs show promise to lower COVID-19's threat

Cholesterol-lowering drugs show promise to lower COVID-19's threat

LMRI scientists discover cause of debilitating eye disease

LMRI scientists discover cause of debilitating eye disease

First genetic cause for a rare eye disease discovered

First genetic cause for a rare eye disease discovered

TSRI chemists invent new method that simplifies late-stage modification of drug molecules

TSRI chemists invent new method that simplifies late-stage modification of drug molecules

Fenofibrate drug may reduce risk of cardiovascular events in patients with type 2 diabetes

Fenofibrate drug may reduce risk of cardiovascular events in patients with type 2 diabetes

ACCORDION study shows lowering blood glucose can reduce progression of diabetic retinopathy

ACCORDION study shows lowering blood glucose can reduce progression of diabetic retinopathy

Combining 2-DG with fenofibrate could provide non-toxic treatments for many cancers

Combining 2-DG with fenofibrate could provide non-toxic treatments for many cancers

Fenofibrate benefits in diabetic retinopathy mediated through PPARα

Fenofibrate benefits in diabetic retinopathy mediated through PPARα

Promising new therapeutic strategy for chronic kidney disease

Promising new therapeutic strategy for chronic kidney disease

Ranbaxy obtains FDA approval to manufacture, market Fenofibrate Capsules USP, 43 mg and 130 mg

Ranbaxy obtains FDA approval to manufacture, market Fenofibrate Capsules USP, 43 mg and 130 mg

Epicure project: an interview with Frédéric Cren

Epicure project: an interview with Frédéric Cren

Salix Pharmaceuticals' total net product revenue increases 90% to $384.4 million in Q1 2014

Salix Pharmaceuticals' total net product revenue increases 90% to $384.4 million in Q1 2014

Impax Laboratories records adjusted net loss of $1.6 million in fourth quarter 2013

Impax Laboratories records adjusted net loss of $1.6 million in fourth quarter 2013

FDA issues final approval for Lupin's sNDA for Antara capsules

FDA issues final approval for Lupin's sNDA for Antara capsules

Par Pharmaceutical receives final ANDA approval for generic version of Trilipix

Par Pharmaceutical receives final ANDA approval for generic version of Trilipix

Santarus, Pharming Group announce FDA acceptance of RUCONEST BLA

Santarus, Pharming Group announce FDA acceptance of RUCONEST BLA